Although there was no added efficacy benefit for nivolumab plus relatlimab in resected melanoma in RELATIVITY-098, pharmacodynamic modulation of IFNγ and target engagement via a reduction in free soluble LAG-3 were similar to those observed in patients with advanced disease in RELATIVITY-047 (ref. 10). The gene discussed is LAG3; the disease is melanoma.